People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.
Study assesses deprescribing claims made by Quebec community pharmacies over a 23-month period, with identification of the most commonly deprescribed medications.
For years, Ambrealle Brown was forced to put her dreams of becoming a nurse on hold due to a life-threatening kidney disease that left her temporarily incapacitated.
